Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Non-Hodgkin 1

Interventions

Cyclophosphamide 91Rituximab 80Specimen Handling 75Magnetic Resonance Spectroscopy 64Biopsy 59Doxorubicin 48Prednisone 47Vincristine 46venetoclax 38obinutuzumab 35fludarabine 34ibrutinib 29Lenalidomide 29Dexamethasone 27Cytarabine 27Methotrexate 25Etoposide 24prednylidene 23CT-P10 23zanubrutinib 22deltacortene 22blinatumomab 22acalabrutinib 22fludarabine phosphate 21Nivolumab 21merphos 18pembrolizumab 16Bendamustine Hydrochloride 16Mercaptopurine 15Calcium Dobesilate 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
efineptakin alfa × Lymphoid × 30 days × Clear all
NCT07052305 2026-05-13

NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma

Washington University School of Medicine

Phase 1 Recruiting
24 enrolled
Lymphoid

Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡